长链非编码RNA PRAL在多发性骨髓瘤患者中的表达及其临床意义

Expression and Clinical Significance of Long Non-Coding RNA PRAL in Patients with Multiple Myeloma

目的:探讨长链非编码RNA PRAL(LncRNA PRAL)在多发性骨髓瘤(MM)患者中的表达及其临床意义。方法:收集本院收治的60例MM患者临床数据资料,并选取同年龄段健康人群60例作为对照,采用实时荧光定量PCR(RT-qPCR)分别测定2组患者血清LncRNA PRAL的表达量,分析其表达与患者临床病理特征及患者预后的关系。结果:LncRNA PRAL在MM患者中的表达较健康者显著下降(F=13.294,P<0.001)。LncRNA PRAL的表达与MM患者D-S分期及ISS分期相关;高表达LncRNA PRAL的MM患者PAD疗效显著提高,中位生存时间显著延长(P<0.05)。结论:LncRNA PRAL在MM患者中的表达降低,高表达LncRNA PRAL的MM患者可获得更好疗效及更长生存时间。

Objective:To investigate the expression and clinical significance of long non-coding RNA PRAL in patients with multiple myeloma(MM).Methods:Clinical data of 60 MM patients and 60 healthy people with the same age(as controls)were selected.Real time-quantitative fluorescence PCR(RT-qPCR)was used to determine the expression levels of serum LncRNA PRAL in the patients and controls,and the relationship of its expression with the clinicopathological characteristics and prognosis of patients was analyed.Results:LncRNA PRAL expression in MM patients was significantly lower than that in healthy people(F=13.294,P<0.001).LncRNA PRAL expression correlated with D-S staging and ISS staging in MM patients.PAD efficacy was significantly improved in MM patients with high expression of LncRNA PRAL,and median survival time was significantly prolonged(P<0.05).Conclusion:LncRNA PRAL expression decreases in MM patients,while MM patients with high expression of LncRNA PRAL can obtain better therapeutic efficacy and longer survival time.